Mesoblast Ltd ADR (MESO)

$15.48 -0.02 (-0.13%)
Market Cap 2.01B
Revenue (ttm) 120.25M
Net Income (ttm) -57.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -47.82%
Debt to Equity Ratio 0.21
Volume 180,100
Avg Vol 234,784
Day's Range N/A - N/A
Shares Out 129.88M
Stochastic %K 3%
Beta 2.12
Analysts Strong Sell
Price Target $37.00

Company Profile

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory infl...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9639 6036
Fax: 61 3 9639 6030
Address:
55 Collins Street, Level 38, Melbourne, Australia
Diane3825
Diane3825 Sep. 8 at 12:27 PM
$MESO
0 · Reply
POINTandSHOOT
POINTandSHOOT Sep. 7 at 6:03 AM
$MESO there’s a lot of runway if things go right
0 · Reply
Diane3825
Diane3825 Sep. 4 at 12:35 PM
$MESO sideways drift until we get the next 4C and Ryoncil sales update in October. Barring any unexpectded news of course. The big catalysts are getting closer by the day! 12 months will see this being an entirely different company $$$
0 · Reply
topstockalerts
topstockalerts Sep. 2 at 1:40 PM
$MESO waking up
1 · Reply
Diane3825
Diane3825 Sep. 2 at 1:07 PM
$MESO
0 · Reply
PatrickandFrankie
PatrickandFrankie Sep. 2 at 3:31 AM
$MESO Me gusta MESO!
1 · Reply
topstockalerts
topstockalerts Sep. 2 at 12:50 AM
After Hours Top Gainers PT2 $SFWL $HKPD $MESO $GRAN $BIAF
0 · Reply
Diane3825
Diane3825 Aug. 28 at 10:15 AM
$MESO
0 · Reply
Diane3825
Diane3825 Aug. 28 at 10:15 AM
$MESO
0 · Reply
BrianRix
BrianRix Aug. 27 at 8:40 PM
$MESO ridiculous that we still trade below 52 week high. This should and will soon climb higher
0 · Reply
Latest News on MESO
Mesoblast price target raised to $39 from $35 at Piper Sandler

2026-08-27T10:45:43.000Z - 17 days ago

Mesoblast price target raised to $39 from $35 at Piper Sandler

MESO

Full Year 2026 Mesoblast Limited Earnings Presentation Transcript

2026-08-27T05:00:11.000Z - 17 days ago

Full Year 2026 Mesoblast Limited Earnings Presentation Transcript

Mesoblast Reports Substantial Revenue Growth to US$120M

Aug 26, 2026, 8:32 PM EDT - 17 days ago

Mesoblast Reports Substantial Revenue Growth to US$120M

MESO

Mesoblast H2 Earnings Call Highlights

Wed, 26 Aug 2026 20:03:21 -0400 - 17 days ago

Mesoblast H2 Earnings Call Highlights

Mesoblast Earnings Call Transcript: H2 2026

Aug 26, 2026, 6:30 PM EDT - 17 days ago

Mesoblast Earnings Call Transcript: H2 2026

Mesoblast Annual report: H2 2026

Aug 26, 2026, 6:30 PM EDT - 17 days ago

Mesoblast Annual report: H2 2026

Mesoblast Slides: H2 2026

Aug 26, 2026, 6:30 PM EDT - 17 days ago

Mesoblast Slides: H2 2026

Mesoblast Earnings release: H2 2026

Aug 26, 2026, 6:30 PM EDT - 17 days ago

Mesoblast Earnings release: H2 2026

Mesoblast Shares Jump 8.82% on ASX as Biotech Rebounds From Friday's Sharp Selloff Tied to State Street Filing

2026-08-17T05:32:33.000Z - 27 days ago

Mesoblast Shares Jump 8.82% on ASX as Biotech Rebounds From Friday's Sharp Selloff Tied to State Street Filing

Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial

2026-08-17T00:50:14.000Z - 27 days ago

Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial

MESO

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

Aug 16, 2026, 8:35 PM EDT - 27 days ago

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

MESO

Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch

Jul 29, 2026, 8:57 PM EDT - 6 weeks ago

Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch

MESO

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

Jul 13, 2026, 8:35 PM EDT - 2 months ago

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

MESO

Mesoblast reported Q4 Ryoncil net revenue of $36M

2026-07-13T15:25:08.000Z - 2 months ago

Mesoblast reported Q4 Ryoncil net revenue of $36M

MESO

Mesoblast rises 6.2%

2026-07-13T14:05:48.000Z - 2 months ago

Mesoblast rises 6.2%

MESO

Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026

Jul 9, 2026, 8:30 PM EDT - 2 months ago

Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026

MESO

Mesoblast Earnings release: Q4 2026

Jul 9, 2026, 4:00 PM EDT - 2 months ago

Mesoblast Earnings release: Q4 2026

Mesoblast receives BLA filing number from FDA for rexlemestrocel-L review

2026-07-01T00:45:14.000Z - 2 months ago

Mesoblast receives BLA filing number from FDA for rexlemestrocel-L review

MESO

Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs

Jun 30, 2026, 8:38 PM EDT - 2 months ago

Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs

MESO

Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility

Jun 24, 2026, 8:59 PM EDT - 2 months ago

Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility

MESO

Mesoblast Slides: Investor presentation

Jun 1, 2026, 6:00 PM EDT - 3 months ago

Mesoblast Slides: Investor presentation

Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

Apr 29, 2026, 8:55 PM EDT - 4 months ago

Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

MESO

Mesoblast Earnings release: Q3 2026

Apr 29, 2026, 8:00 PM EDT - 4 months ago

Mesoblast Earnings release: Q3 2026

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain

Apr 28, 2026, 8:53 PM EDT - 4 months ago

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain

MESO

Mesoblast acquires chimeric antigen receptor platform technology

2026-04-15T01:40:22.000Z - 5 months ago

Mesoblast acquires chimeric antigen receptor platform technology

MESO

Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products

Apr 14, 2026, 8:10 PM EDT - 5 months ago

Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products

MESO

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION

Apr 10, 2026, 4:09 PM EDT - 5 months ago

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION

MESO

Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation

Apr 8, 2026, 9:07 AM EDT - 5 months ago

Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation

MESO

Mesoblast Transcript: R&D Day 2026

Apr 8, 2026, 8:00 AM EDT - 5 months ago

Mesoblast Transcript: R&D Day 2026

Mesoblast Slides: FY 2026

Apr 8, 2026, 8:00 AM EDT - 5 months ago

Mesoblast Slides: FY 2026

Mesoblast receives IND clearance from FDA for Ryoncil trial

2026-04-08T09:29:13.000Z - 5 months ago

Mesoblast receives IND clearance from FDA for Ryoncil trial

MESO

Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy

Apr 7, 2026, 11:35 PM EDT - 5 months ago

Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy

MESO

Mesoblast reports $30.3M in Ryoncil sales in March quarter

2026-04-07T09:30:34.000Z - 5 months ago

Mesoblast reports $30.3M in Ryoncil sales in March quarter

MESO

Mesoblast reports March quarter Ryoncil sales of $30.3M

2026-04-07T01:10:10.000Z - 5 months ago

Mesoblast reports March quarter Ryoncil sales of $30.3M

MESO

Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter

Apr 6, 2026, 9:03 PM EDT - 5 months ago

Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter

MESO

Mesoblast to Host R&D Day on April 8, 2026

Mar 17, 2026, 7:19 PM EDT - 5 months ago

Mesoblast to Host R&D Day on April 8, 2026

MESO

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

Mar 11, 2026, 7:21 PM EDT - 6 months ago

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

MESO

Ryoncil® Profits Underpinning Substantial Growth Pipeline

Feb 26, 2026, 7:42 PM EST - 6 months ago

Ryoncil® Profits Underpinning Substantial Growth Pipeline

MESO

Mesoblast Earnings Call Transcript: H1 2026

Feb 26, 2026, 5:00 PM EST - 6 months ago

Mesoblast Earnings Call Transcript: H1 2026

Mesoblast Quarterly report: H1 2026

Feb 26, 2026, 5:00 PM EST - 6 months ago

Mesoblast Quarterly report: H1 2026

Mesoblast Slides: H1 2026

Feb 26, 2026, 5:00 PM EST - 6 months ago

Mesoblast Slides: H1 2026

Mesoblast Earnings release: H1 2026

Feb 26, 2026, 5:00 PM EST - 6 months ago

Mesoblast Earnings release: H1 2026

Mesoblast Financial Results and Corporate Update Webcast

Feb 20, 2026, 7:00 AM EST - 6 months ago

Mesoblast Financial Results and Corporate Update Webcast

MESO

High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD

Feb 11, 2026, 6:27 PM EST - 7 months ago

High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD

MESO

Ryoncil® Net Revenues Increase for the Quarter to US$30M

Jan 28, 2026, 6:54 PM EST - 7 months ago

Ryoncil® Net Revenues Increase for the Quarter to US$30M

MESO

Mesoblast Earnings release: Q2 2026

Jan 28, 2026, 6:00 PM EST - 7 months ago

Mesoblast Earnings release: Q2 2026

Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment

Jan 26, 2026, 6:45 PM EST - 7 months ago

Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment

MESO

FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy

Jan 18, 2026, 7:01 PM EST - 7 months ago

FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy

MESO

Ryoncil® Sales Increase 60% in December Quarter to US$35.1M

Jan 8, 2026, 6:46 PM EST - 8 months ago

Ryoncil® Sales Increase 60% in December Quarter to US$35.1M

MESO

Mesoblast Announces Changes to Board of Directors' Leadership Roles

Jan 1, 2026, 6:02 PM EST - 8 months ago

Mesoblast Announces Changes to Board of Directors' Leadership Roles

MESO

Mesoblast Registration statement: Registration filing

Dec 30, 2025, 7:00 AM EST - 8 months ago

Mesoblast Registration statement: Registration filing

Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line

Dec 29, 2025, 6:57 PM EST - 8 months ago

Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line

MESO

Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

Dec 11, 2025, 6:22 PM EST - 9 months ago

Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

MESO

Mesoblast Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 4, 2025, 12:00 PM EST - 9 months ago

Mesoblast Transcript: Piper Sandler 37th Annual Healthcare Conference

Mesoblast Participation at Piper Sandler Conference

Dec 3, 2025, 6:10 PM EST - 9 months ago

Mesoblast Participation at Piper Sandler Conference

MESO

Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue

Nov 24, 2025, 6:39 PM EST - 9 months ago

Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue

MESO

Mesoblast Slides: FY 2025

Nov 24, 2025, 6:00 PM EST - 9 months ago

Mesoblast Slides: FY 2025

Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids

Nov 20, 2025, 6:32 PM EST - 9 months ago

Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids

MESO

Mesoblast Transcript: Bell Potter Healthcare Conference 2025

Nov 19, 2025, 6:00 PM EST - 9 months ago

Mesoblast Transcript: Bell Potter Healthcare Conference 2025

James M. O'Brien Appointed Chief Financial Officer at Mesoblast

Nov 17, 2025, 1:52 AM EST - 10 months ago

James M. O'Brien Appointed Chief Financial Officer at Mesoblast

MESO

Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

Nov 4, 2025, 6:40 PM EST - 10 months ago

Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

MESO

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

Oct 19, 2025, 7:48 PM EDT - 10 months ago

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

MESO

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

Oct 6, 2025, 7:24 PM EDT - 11 months ago

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

MESO

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

Oct 2, 2025, 9:04 PM EDT - 11 months ago

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

MESO

Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

Sep 26, 2025, 1:49 AM EDT - 11 months ago

Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

MESO

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

Sep 14, 2025, 9:18 PM EDT - 12 months ago

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

MESO

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

Sep 3, 2025, 9:47 PM EDT - 1 year ago

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

MESO

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

Aug 28, 2025, 8:24 PM EDT - 1 year ago

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

MESO

Mesoblast Earnings Call Transcript: H2 2025

Aug 27, 2025, 6:30 PM EDT - 1 year ago

Mesoblast Earnings Call Transcript: H2 2025

Mesoblast Annual report: H2 2025

Aug 27, 2025, 6:30 PM EDT - 1 year ago

Mesoblast Annual report: H2 2025

Mesoblast Annual report: H2 2025

Aug 27, 2025, 6:30 PM EDT - 1 year ago

Mesoblast Annual report: H2 2025

Mesoblast Slides: H2 2025

Aug 27, 2025, 6:30 PM EDT - 1 year ago

Mesoblast Slides: H2 2025

Mesoblast Earnings release: H2 2025

Aug 27, 2025, 6:30 PM EDT - 1 year ago

Mesoblast Earnings release: H2 2025

Successful Commercial Launch of Ryoncil®

Jul 17, 2025, 8:38 PM EDT - 1 year ago

Successful Commercial Launch of Ryoncil®

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

Jun 30, 2025, 8:36 PM EDT - 1 year ago

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

Jun 11, 2025, 9:24 PM EDT - 1 year ago

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

May 14, 2025, 10:57 PM EDT - 1 year ago

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

Apr 29, 2025, 8:53 PM EDT - 1 year ago

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Apr 28, 2025, 7:44 PM EDT - 1 year ago

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Apr 16, 2025, 9:20 PM EDT - 1 year ago

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs

Apr 3, 2025, 6:58 PM EDT - 1 year ago

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Apr 2, 2025, 7:15 PM EDT - 1 year ago

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

First Three Children to Commence Treatment With Ryoncil®

Mar 30, 2025, 7:39 PM EDT - 1 year ago

First Three Children to Commence Treatment With Ryoncil®

Ryoncil® is Now Available for Purchase in the United States

Mar 26, 2025, 8:19 PM EDT - 1 year ago

Ryoncil® is Now Available for Purchase in the United States

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

Mar 13, 2025, 7:42 PM EDT - 1 year ago

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

Diane3825
Diane3825 Sep. 8 at 12:27 PM
$MESO
0 · Reply
POINTandSHOOT
POINTandSHOOT Sep. 7 at 6:03 AM
$MESO there’s a lot of runway if things go right
0 · Reply
Diane3825
Diane3825 Sep. 4 at 12:35 PM
$MESO sideways drift until we get the next 4C and Ryoncil sales update in October. Barring any unexpectded news of course. The big catalysts are getting closer by the day! 12 months will see this being an entirely different company $$$
0 · Reply
topstockalerts
topstockalerts Sep. 2 at 1:40 PM
$MESO waking up
1 · Reply
Diane3825
Diane3825 Sep. 2 at 1:07 PM
$MESO
0 · Reply
PatrickandFrankie
PatrickandFrankie Sep. 2 at 3:31 AM
$MESO Me gusta MESO!
1 · Reply
topstockalerts
topstockalerts Sep. 2 at 12:50 AM
After Hours Top Gainers PT2 $SFWL $HKPD $MESO $GRAN $BIAF
0 · Reply
Diane3825
Diane3825 Aug. 28 at 10:15 AM
$MESO
0 · Reply
Diane3825
Diane3825 Aug. 28 at 10:15 AM
$MESO
0 · Reply
BrianRix
BrianRix Aug. 27 at 8:40 PM
$MESO ridiculous that we still trade below 52 week high. This should and will soon climb higher
0 · Reply
JFais
JFais Aug. 27 at 2:49 PM
$MESO (L) Posted my Q2 call notes in Chat- another setup I see relatively little on elsewhere 1,100 patents/pending, IP to 2044 (long runway= high strategic value to acquirer) First-mover advantage (first and only mesenchymal stromal cell product approved by the FDA), complex manufacturing + unique know-how for scaling up $10B TAM in CLBP alone, then layer in SR-aGvHD, heart failure & DMD among others Also, burn rate of just $17.3M for back half of fiscal year (like how lean the operation is)
0 · Reply
Diane3825
Diane3825 Aug. 27 at 12:55 PM
$MESO
0 · Reply
Diane3825
Diane3825 Aug. 27 at 12:55 PM
$MESO
0 · Reply
Diane3825
Diane3825 Aug. 27 at 12:54 PM
$MESO
0 · Reply
AlertsAndNews
AlertsAndNews Aug. 27 at 2:46 AM
$MESO Mesoblast Reports Substantial Revenue Growth to US$120M Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: "We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. The financial result is a product of continued growth in RYONCIL market adoption and focus on disciplined capital allocation while investing in our high-value opportunities."
1 · Reply
WhaleClues
WhaleClues Aug. 27 at 2:36 AM
$MESO
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 27 at 12:26 AM
$MESO Q2 '26 Earnings Results & Recap For FY26, Mesoblast reported total revenues of $120.3M, driven by net product sales of $115.2M, and reduced its net loss by 44% to $57.5M, or 4.44 cents per share.
0 · Reply
Diane3825
Diane3825 Aug. 25 at 4:41 PM
$MESO https://www.marketscreener.com/news/mesoblast-financial-results-and-corporate-update-webcast-ce7858dbdb8df724 I wonder what updates we will get along with the annual report out. Revascor BLA progress? Ryoncil sales commentary? Adult GVHD trial updates? New technology developements? So many positives coming up!
1 · Reply
Posna
Posna Aug. 22 at 10:59 AM
$MESO I was Fond of the 17s 🤢
1 · Reply
JBourne0970
JBourne0970 Aug. 18 at 10:17 PM
$MESO new here... holy sht this looks good
1 · Reply
Diane3825
Diane3825 Aug. 18 at 4:51 PM
$MESO
0 · Reply
Diane3825
Diane3825 Aug. 18 at 4:51 PM
$MESO
0 · Reply